Literature DB >> 32154748

Stevens-Johnson syndrome and toxic epidermal necrolysis: risk factors, causality assessment and potential prevention strategies.

Chu-Chi Lin1,2, Chun-Bing Chen1,2,3,4,5,6,7, Chuang-Wei Wang1,2, Shuen-Iu Hung2, Wen-Hung Chung1,2,3,5,6,7.   

Abstract

Introduction: The clinical manifestations of cutaneous adverse drug reactions are variable with different severity. Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are life-threatening severe cutaneous adverse reactions (SCARs) majorly caused by drugs and mediated by cytotoxic T cells.Areas covered: In this review, we focus on risk factors that contribute to the development of SJS/TEN and review the updated immune mechanism, preventive strategies as well as current therapeutic approaches for SJS/TEN.Expert opinion: The progress of SJS/TEN researches reveals that cytotoxic T cells majorly activated by drug interacted with the human leukocyte antigen (HLA) and T cell receptors play an important role for the immune mechanism of SJS/TEN. Several clinical assessment tools and in vitro drug-T cells activation tests have been developed to identify the causality of SJS/TEN. New therapeutic approaches and biologics such as TNF-alpha antagonist have been conducted to improve the prognosis of SJS/TEN.

Entities:  

Keywords:  Human leukocyte antigen (HLA); Stevens-Johnson syndrome (SJS); T cell receptors; severe cutaneous adverse reactions; toxic epidermal necrolysis (TEN)

Mesh:

Substances:

Year:  2020        PMID: 32154748     DOI: 10.1080/1744666X.2020.1740591

Source DB:  PubMed          Journal:  Expert Rev Clin Immunol        ISSN: 1744-666X            Impact factor:   4.473


  1 in total

1.  The Gene Expression Deconvolution Interactive Tool (GEDIT): accurate cell type quantification from gene expression data.

Authors:  Brian B Nadel; David Lopez; Dennis J Montoya; Feiyang Ma; Hannah Waddel; Misha M Khan; Serghei Mangul; Matteo Pellegrini
Journal:  Gigascience       Date:  2021-02-16       Impact factor: 6.524

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.